Modality
ERT
MOA
PARPi
Target
PI3Kα
Pathway
Wnt
GBMAlzheimer's
Development Pipeline
Preclinical
~Feb 2015
→ ~May 2016
Phase 1
~Aug 2016
→ ~Nov 2017
Phase 2
Feb 2018
→ Aug 2027
Phase 2Current
NCT07743122
687 pts·GBM
2018-02→2027-08·Terminated
687 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-08-101.4y awayPh2 Data· GBM
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P2
Termina…
Catalysts
Ph2 Data
2027-08-10 · 1.4y away
GBM
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07743122 | Phase 2 | GBM | Terminated | 687 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| Cevifotisoran | Neurocrine | Approved | CD47 |